Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419532 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT04419532: Active Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Daiichi Sankyo.
NCT04419532 is a Phase 1 study of Solid Tumor and Advanced Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 40 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04419532, a Phase 1 study of Solid Tumor and Advanced Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
Primary Outcome
A dose-limiting toxicity (DLT) is defined as any treatment-emergent adverse event (TEAE) that occurs during the DLT evaluation period (21 days), excluding toxicities clearly related to disease progression or intercurrent illness or to concomitant medications or to concomitant procedures and is Grade 3 or above according to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0, with certain specified exceptions.
Conditions Studied
Interventions
- DRUG DS-1055a
Study Locations (6)
Other
- National Cancer Center Hospital - Chūōku
- National Cancer Center Hospital East - Kashiwa
- Cancer Institute Hospital of JFCR - Kōtoku
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati Cancer Center - Cincinnati
Ontario
- Princess Margaret Cancer Center - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
What the registry record for NCT04419532 still lists
NCT04419532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which DS-1055a is the first listed.
NCT04419532 lists 6 locations in 4 states (Other, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT04419532 about?
NCT04419532 is a clinical study titled "A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
What is the current status of trial NCT04419532?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-09. Estimated completion is 2027-07-01.
What conditions does trial NCT04419532 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor.
What interventions are being tested in trial NCT04419532?
The interventions under investigation include: DS-1055a (DRUG).
Who is sponsoring clinical trial NCT04419532?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04419532 being conducted?
This trial has 6 study locations across New York, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04419532's enrollment target sits among peer trials
40 141st of 196 higher than 54 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI